Drug Trial Radar · NCT03699475
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
Last checked: Nov 19, 2026Latest source record: Sep 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1
Actual
Start
Dec 27, 2018
Primary completion
Jul 23, 2019
Study completion Jul 23, 2019
Sponsor
- Lead sponsor
- Bellicum PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Oct 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study compares the safety and effectiveness of giving rivogenlecleucel (BPX-501 T cells) to patients with AML or MDS post haploidentical hematopoietic stem cell transplant compared to post-transplant cyclophosphamide.
Conditions
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
Interventions
rivogenlecleucelBiological
Biological: T cells transduced with caspase 9 safety switch
rimiducidDrug
administered to inactivate rivogenlecleucel in the event of GVHD
CyclophosphamideDrug
GVHD prophylaxis
haplo-HSCTProcedure
treatment for disease
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects Experiencing 3 or More Dose Limiting Toxicities [Phase 2] Within a 100-day DLT Window After Receiving BPX-501Time frame: 100 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
TriStar Bone Marrow Transplant, LLC
Nashville, Tennessee
Methodist Healthcare System of San Antonio Clinical Trials Office
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.